{"id":"W1998827682","doi":"10.1186/1471-2407-11-420","title":"The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity","year":2011,"lang":"en","type":"article","venue":"BMC Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; Centre for Drug Research and Development; BC Cancer Agency","funders":"National Cancer Institute; Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance","keywords":"Gefitinib; Trastuzumab; In vivo; Cytostasis; Medicine; Cancer research; Everolimus; Breast cancer; SKBR3; PI3K/AKT/mTOR pathway; Pharmacology; Cell growth; Growth inhibition; Surgical oncology; Vinorelbine; Cancer; Oncology; Signal transduction; Internal medicine; Cytotoxicity; Epidermal growth factor receptor; In vitro; Biology; Chemotherapy; Cisplatin","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001288289,0.0002971321,0.0004165985,0.0002685379,0.00009021077,0.000228325,0.0001995428,0.0001994481,0.00110698],"category_scores_gemma":[0.0001063217,0.00009880907,0.0002166711,0.0001760965,0.0001367853,0.0001046409,0.0001199905,0.0003497782,0.0003242744],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002030251,"about_ca_system_score_gemma":0.0002281222,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003116704,"about_ca_topic_score_gemma":0.0009422344,"domain_scores_codex":[0.9998578,0.00002908423,0.00001579276,0.00002311458,0.00004396402,0.00003025493],"domain_scores_gemma":[0.9999393,0.00001248309,0.00001622739,0.000008831558,0.000006940986,0.00001618825],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0008714966,0.0003540837,0.0008378547,0.0001047792,0.00004340509,0.00007823259,0.00001698927,0.0004023786,0.9857023,0.00009778,0.0002501552,0.01124046],"study_design_scores_gemma":[0.0001548051,0.004773496,0.008342407,0.000007936328,0.00007049234,0.0007341559,0.00001534916,0.001198989,0.9803962,0.00002361952,0.004272285,0.00001020777],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9933575,0.002643023,0.0009250339,0.00008664076,0.0000394725,0.0000459169,0.000182915,0.0001004952,0.002619044],"genre_scores_gemma":[0.9960335,0.0009047671,0.001183401,0.00002808128,0.0000193102,0.00003926918,0.0002676395,0.000009300122,0.001514607],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00110698,"threshold_uncertainty_score":0.003703237,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04481471223116713,"score_gpt":0.3216014584420963,"score_spread":0.2767867462109291,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}